当前位置:首页>产品中心>单抗/多抗>HEK293T Human CD193/CCR3 Stable Cell Line|HEK293T人CD193/CCR3稳定细胞系(靶标:人CD193/CCR3稳定表达细胞系)

HEK293T Human CD193/CCR3 Stable Cell Line|HEK293T人CD193/CCR3稳定细胞系(靶标:人CD193/CCR3稳定表达细胞系)

  • 货号:RB9THW620818
  • 价格:面议
  • 点击:378

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标CD193/CCR3
稳定性和储存Frozen in liquid nitrogen.
登录号P51677
背景信息

C-C chemokine receptor type 3 (CD193/CCR3) is a ~41 kDa protein. G protein-coupled receptor (GPCR) that plays a key role in the immune system by regulating the migration and activation of white blood cells in response to chemokines. Selectively interacts with eosinophil-attracting chemokines such as eotaxin/CCL11, eotaxin-2/CCL24 and eotaxin-3/CCL26. Ligand binding triggers intracellular signaling that leads to chemotaxis of immune cells. Mechanistically, signals through GNA14 or GNA16 to induce stimulation of phospholipase Cbeta/PLCB2 and subsequently chemotaxis. Alternatively, transduces signal via GNAI1 resulting in elevated intracellular calcium levels and activation of the PI3K/AKT pathway.

1. Song, Y. et al. (2018) Biochemistry 57, 852-860. PMID: 28994588
2. Combadiere, C. et al. (1995) The Journal of biological chemistry 270, 16491-4. PMID: 7622448
3. Daugherty, BL. et al. (1996) The Journal of experimental medicine 183, 2349-54. PMID: 8642344
4. Ponath, PD. et al. (1996) The Journal of experimental medicine 183, 2437-48. PMID: 8676064
5. Tian, Y. et al. (2008) Cellular signalling 20, 1179-89. PMID: 18406577
6. Shao, Z. et al. (2022) Cell discovery 8, 44. PMID: 35570218
7. Park, JS. et al. (2018) International journal of biological macromolecules 120, 835-845. PMID: 30171954
产品特性Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
种属Human
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 540
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 637
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 531
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 401
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 527
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 537
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 480
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 485
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 355
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 421
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 662
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 571
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 663
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 535
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 327
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 577
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 683
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 704
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 645
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 488
总计 33037 个记录,共 1652 页,当前第 1651 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00